Abstract
Purpose :
To evaluate the Sentio Platform’s (Adaptive Sensory Technology, Boston) suitability for clinical application of computer-adaptive contrast sensitivity function (CSF) assessment compared to traditional letter acuity in patients with macula-involving retinal detachment (RD) and central serous retinopathy (CSR).
Methods :
Following approval by the University of Michigan School of Medicine’s Institutional Review Board, all eligible participants had the following criteria: age 18 years or older; and 1 study eye with macula-involving retinal detachment or central serous retinopathy. Best corrected Snellen and ETDRS (Early Treatment Diabetic Retinopathy Study) visual acuities were obtained from consented participants. Participants also completed an in-office CSF test.
Results :
The mean age of all participants was 58 years (range 47 to 73). 3 participants had macula-involving RD and 3 participants had CSR. Mean visual acuity in macula-involving RD and CSR eyes, respectively, was logMAR 0.41 (20/50) and logMAR 0.22 (20/32). Mean visual acuity in control eyes was 0.03 (20/20). In macula-involving RD and CSR eyes, mean CSF area under the curve (AUC), a measure of all letters seen across all contrast levels, respectively was 0.67 and 1.16. Mean CSF AUC in control eyes was 1.39. In a macula-involving RD eye in which the logMAR was -0.125 (20/16), the CSF AUC was 1.37; in control eyes in which the logMAR was 0 or less (20/20 or better), the CSF AUC was 1.47. Macula-involving RD eyes with poor visual acuity, logMAR 0.875 (20/125) and logMAR 0.477 (20/50-20/63), had CSF AUC of 0.15 and 0.50.
Conclusions :
These data suggest that the CSF assessment may detect differences in vision in patients with macula-involving retinal detachment and central serous retinopathy that may not be detectable with traditional visual acuity testing. In a macula-involving RD eye with visual acuity of 20/15, the CSF AUC was lower than the average CSF AUC of control eyes with visual acuity of 20/20 or better. Also, eyes with a poor visual acuity had a lower CSF AUC. Further studies and longitudinal follow-up would be needed to determine if this device has a role in vision assessment of patients with macula involving disease processes.
This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.